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Abstract 
Background 
Huntington’s disease is characterised by a range of motor, psychiatric and cognitive 
symptoms. These present in different combinations through the disease course and impact 
on daily life and functioning. Huntington’s disease is caused by a dominant CAG repeat 
expansion in the HTT gene, and longer repeats are associated with earlier onset of motor 
symptoms. 
Objectives 
To investigate the onset, prevalence and functional impact of motor and psychiatric 
symptoms of Huntington’s disease. 
Methods 
We analysed clinical phenotype data from the European REGISTRY study for 6316 
individuals with manifest Huntington’s disease. Onset and prevalence data for motor and 
psychiatric symptoms were extracted from the clinical history part of REGISTRY and the 
detailed Clinical Characteristics Questionnaire. Generalised linear models were constructed 
to assess relationships between symptoms and functional outcomes. 
Results 
As age at first presentation of Huntington’s disease increases, the likelihood that the initial 
presenting symptom is motor also increases. This is not associated with pathogenic CAG 
repeat length. At a population level there were conserved relationships between symptoms 
across different repeat lengths, with depression often occurring early followed by motor 
and then cognitive symptoms. There were significant relationships between all individual 
psychiatric and cognitive symptoms and reduced functional capacity. 
Conclusions 
There are conserved patterns of symptoms in HD that can be quantified. Psychiatric and 
behavioural symptoms significantly impair daily functioning and should be considered part 
of the disease trajectory at any age.  
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Introduction 
Huntington’s disease (HD) is an autosomal dominant central neurodegeneration caused by 
an expanded CAG tract in exon 1 of the Huntingtin gene (HTT)1. Degeneration is most 
prominent in the medium spiny neurons of the striatum but occurs widely in the brain, 
leading to a progressive movement disorder, usually involving chorea, cognitive decline and 
ultimately death. In addition, individuals with HD develop a variable constellation of 
debilitating behavioural and psychiatric symptoms alongside their motor problems2,3. The 
length of the CAG expansion is inversely correlated with the age at onset of disease 
symptoms and accounts for up to 70% of the variance observed in motor onset, as 
determined by a clinical rater4–9. 
Clinical onset of the first symptom of HD has been used as a specific identifiable milestone 
in the natural history of the disease in an individual. It has proven particularly useful in 
recent studies of genes that modify the onset of HD10,11, although it is only a crude measure 
of the lifelong pathological process. Onset information is typically recorded by a rating 
physician in observational studies such as the European REGISTRY12–14. The rater also 
records the initial major presenting symptom out of a choice of six: motor, cognitive, 
psychiatric, oculomotor, other or mixed. Later versions of REGISTRY incorporated the HD 
Clinical Characteristics Questionnaire (HD-CCQ)12 to ask individuals with HD whether they 
had experienced a range of motor and psychiatric symptoms, and at what age those 
symptoms started15. The symptom groupings recorded were motor, depression, irritability, 
violent or aggressive behaviour, apathy, perseverative/obsessive behaviour, psychosis and 
cognitive impairment sufficient to impact on work or daily living. Importantly, individuals 
with HD were asked to report the presence or absence of these symptoms independent of 
whether they considered them directly related to HD or not. These symptom onset data 
were collected alongside multiple other assessments of HD phenotype, including the Unified 
Huntington’s Disease Rating Scale (UHDRS)16. The UHDRS consists of a series of validated 
questionnaires, tools and examinations related to motor, cognitive, behavioural and 
functional impairments seen in HD. 
To address the onset and relationships of multiple symptoms in individuals with HD, we 
analysed detailed phenotypic data from over 6000 participants in the REGISTRY study. We 
highlight how the presenting symptoms of HD vary with age at onset and CAG repeat length. 
We find that on average there is a consistent disease trajectory for HD with depression 
often occurring earliest, followed by motor symptoms and then later apathy and cognitive 
decline. We show that the presence of psychiatric symptoms is significantly associated with 
reduced functional capacity, highlighting the importance of recognising and managing these 
common features of HD. 
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Methods 
HD participants 
Participants were in the multicentre, multinational, observational REGISTRY study of 
European HD (http://www.euro-hd.net/html/REGISTRY) and data were accessed as part of 
European Huntington’s disease Network (EHDN) data mining project 0791. Ethical approval 
for REGISTRY was obtained in each participating country, and all participants gave written 
informed consent. 
Participant data 
HD participant data, collected between June 2004 and February 2016 across 161 sites in 17 
European countries, was obtained for 6316 individuals who had a recorded HD age at onset, 
determined by the rating clinician in REGISTRY, and a confirmed pathogenic CAG length 
between 36-93 CAGs. Of these CAG sizes, 5027 had been centrally determined by BioRep 
Inc. (Milan, Italy) in line with REGISTRY protocols (https://www.enroll-
hd.org/enrollhd_documents/2016-10-R1/REGISTRY-protocol-3.0.pdf), and 1289 had been 
derived from local diagnostic laboratories. Two onset estimates were used in this study. 
Firstly, the clinician’s estimate of age at clinical HD onset (sxrater) was determined using all 
available clinical evidence at the first REGISTRY visit. This was a requirement for 
incorporation into this study. It additionally classified onset type as motor, cognitive, 
psychiatric, oculomotor, other or mixed. As the clinician’s estimate was given as a date, age 
estimates were calculated using the participant’s anonymised birthday; where only a year 
was given, July 15th was used for estimation (15/07/xxxx). Second, symptom onsets were 
determined from the HD Clinical Characteristics Questionnaire (HD-CCQ) which was 
completed by a healthcare professional using responses from the individual with HD and 
their carer/partner. HD-CCQ comprises questions about eight symptoms seen in HD and in 
our study information was available, at least in part, for 5609 individuals: motor (data from 
5603 individuals), cognitive (5591), apathy (5584), depression (5595), 
perseveration/obsessive behaviour (5588), irritability (5586), violent or aggressive 
behaviour (5586) and psychotic symptoms (5589). For each symptom, the participant was 
asked if they had ever had the symptom (yes or no), and, if yes, the age the symptom was 
first experienced. For subsequent analyses, missing data were handled using pairwise 
deletion to maximise the number of individuals. Typically, the rater estimate of onset and 
initial HD-CCQ would be recorded at the first REGISTRY visit, sometimes by the same 
clinician or sometimes by separate staff members depending on local clinic set-up. 
Subsequent visits would update the HD-CCQ: we used data from the most recent clinic visit. 
Statistical analyses of clinical data 
To calculate coefficients of determination (R2 values), HD-CCQ age at onset data were 
natural log transformed. Only individuals with a known sex and a symptom onset ≥3 years 
were considered, and a residual vs leverage plot identified one influential data point passing 
Cook’s distance that was removed from all R2 calculations. P values were calculated 
comparing male and female R2 values using Fisher’s transformation17. A chi-square test was 
used to test for differences in symptom frequency, derived from the yes/no component of 
the HD-CCQ, between males and females. Associations between binary responses in the HD-
CCQ (1; experienced the symptom and 0; symptom not experienced) and clinical covariates 
were tested using logistic regression. Analysis was restricted to HD participants with 40-55 
CAGs, a total functional capacity (TFC) score >0, and a clinical onset ≥20 years. The 
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covariates used were sex, CAG length, alcohol consumption (units per week), tobacco use 
(cigarettes per day), education (years of education), total functional capacity score and total 
motor score (TMS). An additional analysis regressed the type of HD onset defined by the 
clinician, coded as a binary variable, on the clinician’s onset or CAG length (Table S2). Finally, 
we tested whether symptom presence was associated with the length of the wild-type (6-35 
CAGs) and expanded CAGs (36-93 CAGs) alleles in individuals of known sex, and for whom 
both CAG lengths were known (Table S3). 19 individuals with a recorded co-morbidity of 
schizophrenia, schizotypal disorder or schizoaffective disorder (ICD-10 F20, F21 or F25) were 
excluded from all models. It was not possible to formally exclude these symptoms being 
part of the HD phenotype in these few individuals. Statistical analysis used R (version 3.6.0; 
R core team, 2019, https://www.r-project.org/). 
Results 
The initial symptom of HD varies with age and CAG length 
We analysed the initial major symptom at HD clinical onset for 6316 participants with 
manifest disease in REGISTRY12. All participants had a confirmed genetic diagnosis of HD 
with a pathogenic CAG repeat length of 36-93 (Fig. S1). The initial major symptom at onset, 
determined by the rating physician, varied with the age at which HD became clinically 
manifest (Fig. 1A and Table S1). Individuals with onset before the age of 20, usually 
categorised as Juvenile Huntington’s disease (JHD), were equally likely to present with 
motor symptoms (24.5%), cognitive symptoms (21.8%) or psychiatric symptoms (28.2%). In 
contrast, for adult-onset HD motor presentations became significantly more likely (P = 7.4 x 
10-22) and psychiatric presentations significantly less likely (P = 9.4 x 10-16) as age at first
symptom increased (Fig. 1A and Table S2A).  For people presenting over the age of 60,
68.6% had motor symptoms at clinical onset with just 11.5% having psychiatric and 6.7%
cognitive presentations. Next, we tested whether there was any relationship between
pathogenic CAG repeat length, known to be inversely correlated with age at symptom
onset, and the presenting phenotype. Interestingly, there was no significant relationship
between CAG length (36-59 inclusive) and the relative proportions of motor, cognitive and
psychiatric onset cases (Fig. 1B and Table S2B). For the few cases with data and repeat
lengths of more than 59 CAG we observed a more balanced distribution of motor, cognitive
and psychiatric onsets, mirroring the trends seen for the JHD cases.
Psychiatric symptoms are common in HD with onsets captured by the Clinical 
Characteristics Questionnaire 
The HD Clinical Characteristics Questionnaire (HD-CCQ) gathers information directly from 
individuals with HD and their carers/companions about whether they have ever had a range 
of motor, psychiatric and behavioural symptoms, and at what age these symptoms were 
first experienced. Importantly, symptoms are recorded whether or not they are considered 
part of HD in that individual. We analysed the lifetime prevalence of these eight symptoms 
in 5609 individuals with HD at their most recent recorded clinic visit and compared males 
and females (Table 1). The mean age (± standard deviation) at last recorded clinic visit was 
53.3 ± 13.0 years. Almost all (>99%) individuals with HD had experienced motor symptoms 
and there was no difference in prevalence between males and females. The next most 
prevalent symptom was depression, occurring in 64.5% of HD individuals with significantly 
6 
more females affected than males (70.4% vs 58.2%; P = 2.6 x 10-21). Cognitive impairment 
sufficient to impact upon work or activities of daily living, apathy and irritability were also 
each observed in over half of our HD population. Cognitive impairment and apathy were 
equally likely in males and females, but there was significantly more irritability observed in 
males (62.9% vs 56.9%; P = 4.0 x 10-6). An excess of violent or aggressive behaviour was also 
observed in the male group (34.9% vs 27.0%; P = 2.0 x 10-10). Psychosis was the least 
prevalent of the eight recorded symptoms, although this was still observed in over 11% of 
individuals with HD with no significant difference in prevalence between males and females. 
To assess the reliability of HD-CCQ symptom data we compared the age at first clinical onset 
of HD, as determined by the rating physician in REGISTRY, to the age at relevant symptom 
onset recorded from patients/carers in HD-CCQ for three different onset groups: motor, 
cognitive and psychiatric (Fig. S2). There was very strong correlation between ages at first 
motor symptom onset, whether rater-determined or from HD-CCQ (Fig. S2A). 92.1% 
(N=2604) had the two recorded motor onsets within 2 years of each other. Similarly, there 
was strong correlation between ages at cognitive symptom onset, whether rater-
determined or from HD-CCQ (Fig. S2B). 76.7% (N=277) had clinician and HD-CCQ onsets 
within 2 years of each other. Most of the discrepancies occurred where the clinician’s 
estimate at onset was earlier than the HD-CCQ (20.2%; N=77), probably reflecting the more 
stringent requirement in HD-CCQ for cognitive impairment to impact on work and/or daily 
life. Finally, there was also good correlation between ages at first psychiatric symptom onset 
whether rater-determined or as part of HD-CCQ, although the data were more dispersed 
(72.7%; N=905 within 2 years of each other; Fig. S2C). 19.5% (N=243) had HD-CCQ 
psychiatric onset over 2 years before their rater-determined HD (psychiatric) onset, 
probably reflecting coincident mental health issues such as depression that are prevalent in 
the general population but not necessarily attributable to HD. Overall, these data provide 
some support for using HD-CCQ data in quantitative analyses of HD phenotypes.  
Presence of psychiatric symptoms is associated with CAG repeat length 
To assess the temporal relationships of different symptoms in HD we plotted mean age at 
symptom onset from HD-CCQ against CAG repeat length for different symptoms (Fig. 2). 
There was a strong inverse correlation between pathogenic CAG repeat length (40-55 CAG 
inclusive) and mean age at symptom onset for all symptoms analysed. We found no effect 
of wild-type CAG allele length on any symptom onset, nor any significant statistical 
interaction between expanded and wild-type repeat lengths (Table S3). Pathogenic CAG 
length explained 66.3% of the variance in age at onset of motor symptoms, in line with 
previous estimates4–6,9,18–22, but also between 37.5% and 61.9% of the variance in onset of 
each of the psychiatric symptoms analysed (Table 2). Depression had the weakest 
association with CAG repeat length (R2= 37.5%), likely reflecting the high prevalence of the 
symptom in the general population independent of HD. CAG length accounted for 
significantly more of the variance in age at onset of perseverative/obsessive behaviour in 
males (Table 2; P = 3.7 x 10-3) and irritability in females (P = 1.3 x 10-3). 
The onsets of motor and psychiatric symptoms in HD are temporally related 
Consistent relationships were observed between many of the symptoms across different 
repeat lengths (Fig. 2 and Table S4). Depression usually had the earliest mean age at onset, 
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followed by motor impairment and then apathy and cognitive impairment as the latest 
symptoms. Onset of irritability preceded motor onset at shorter repeat lengths (40-43 CAGs, 
inclusive) but tended to follow it at longer repeat lengths (44-53 CAGs, inclusive). 
Perseverative/obsessive behaviour tended to occur later in the disease course, similar to 
cognitive impairment, whereas violent or aggressive behaviour tended to follow irritability. 
The mean age at onset of psychosis was variably placed, in part due to the smaller number 
of HD individuals who reported the symptom, although it usually occurred later in the 
disease course. The mean difference in years from onset of first symptom to last decreased 
with CAG repeat length from approximately 8 years for 40 repeats to 4 years for 55 repeats 
(Fig. 2). Plotting the difference in age between motor onset and the onset of a specific 
psychiatric symptom for all the individuals in our study underscored the variable 
presentation of symptoms at an individual level (Fig. S3). 
Psychiatric symptoms are significantly associated with reduced functional capacity 
To assess whether motor and psychiatric symptoms were associated with altered functional 
abilities we used multiple logistic regression (Table 3). This analysis incorporated sex, 
pathogenic CAG length, alcohol consumption, tobacco use, educational attainment, total 
functional capacity score and total motor score as predictors of the presence/absence of 
each HD-CCQ symptom. The presence of any of the psychiatric symptoms was significantly 
associated with a lower total functional capacity score, an indication of impaired ability to 
work, manage personal finances and function independently. In addition, depression was 
significantly more prevalent in females (P = 2.5 x 10-6), and irritability significantly more 
prevalent in males (P = 3.7 x 10-3). Violent or aggressive behaviour was also nominally 
associated with male sex (P = 2.2 x 10-2). Total motor score was significantly and positively 
associated with the presence of motor symptoms (P = 1.5 x 10-4), as expected. Depression 
was significantly associated with a lower total motor score (P = 3.4 x 10-5), indicating its 
onset at an early stage of HD. Finally, significant associations were observed between 
tobacco use and irritability (P = 3.1 x 10-3), and between lower educational attainment and 
psychosis (P = 4.7 x 10-4). 
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Discussion 
In this study of over 6000 patients we have shown that the initial clinical presentation of HD 
varies with age: late onset (>60 years) is usually associated with motor symptoms, whereas 
early onset (<20 years; JHD) is associated with variable motor, cognitive or psychiatric 
presentations (Fig. 1A). A previous smaller study using REGISTRY found that 65.5% of the 
late onset cohort (defined as >59 years) had motor symptoms recorded first, with chorea 
and gait/balance problems most common23. We note that cognitive onset of HD might be 
under-reported in older age-groups due to it being regarded as coincident ‘age-related’ 
change. JHD is known to present more variably24–26 and motor phenotypes in younger 
patients are not always captured effectively by the UHDRS motor scores which are weighted 
towards chorea and dystonia rather than the rigidity often seen in JHD27,28. Importantly, our 
results show little relationship between pathogenic repeat length and onset type (Fig. 1B), 
despite CAG repeat length being highly correlated with age at first symptom onset. Overall, 
these data suggest that the age at onset of symptoms in an individual is determined by CAG 
repeat length in combination with other genetic and environmental factors. The resultant 
age at which onset occurs then influences the types of symptoms that becomes manifest, 
particularly in the youngest and oldest age ranges. Consistent with this idea, recent genetic 
studies have shown that variants at modifier loci across the genome contribute to 
differences in the age at onset of motor symptoms and disease progression in HD11,29,30. 
Most modifier studies of HD have used age at motor onset as a quantitative trait, as 
diagnosis of motor signs in the context of an expanded CAG repeat in HTT has high 
specificity for HD and most individuals with manifest HD will have motor symptoms. This is 
reinforced by the high concordance between the onset of motor symptoms captured by the 
rating physician in REGISTRY and those recorded from patients/carers in HD-CCQ (92.1%; 
Fig. S2). Therefore, although motor onset is mostly captured retrospectively and can be 
difficult to pinpoint, it is the most reliable of the onset characteristics in this study. In 
situations where the initial presentation of HD is psychiatric it is reasonable to use HD-CCQ 
motor onset in analyses. 
Psychiatric, cognitive and behavioural symptoms (Table 1) are significantly more prevalent 
in HD than in the non-HD population3,15,31,32. The HD-CCQ captures unique quantitative 
information regarding symptom prevalence and onset, and does not judge whether 
symptoms are HD-related or not. The concordance between symptom onset recorded by 
the rating physician in REGISTRY and that recorded in HD-CCQ for cognitive and psychiatric 
symptoms, although not as strong as for motor symptoms, provides some validation for 
using HD-CCQ data in genetic and other analyses (Fig. S2). 
We saw a significant influence of the expanded CAG but no influence of the wild-type CAG 
length on onset age for any symptom in the HD-CCQ. While an influence of the normal HTT 
CAG allele on onset was previously reported in small HD cohorts33–36, a recent much larger 
study determined there was no influence of the normal HTT allele18. All symptom onsets 
were inversely correlated with CAG length (Fig. 2) with motor symptoms best correlated and 
depression least correlated (Table 2). These data are consistent with previous reports 
showing that CAG length accounts for 47-72% of the variance in age at clinical onset of HD37. 
As exact CAG length, not polyglutamine length, is now known to be important in 
determining age at onset11,38,39, improved CAG sizing measures are likely to increase the 
accuracy of correlations between repeat length and symptoms39. Previous studies detected 
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no correlation of CAG repeat length and the presence of psychiatric symptoms measured 
using a variety of psychiatric instruments40–43. However, these studies were small and often 
examined incident psychiatric symptoms, which can fluctuate over time, rather than lifetime 
history as here. 
The average pattern of onset of different symptoms in HD was strikingly conserved across 
CAG repeat lengths of 40-50 (Fig. 2). The mean age at onset of depression is earliest at each 
repeat length followed by irritability and motor symptoms and then apathy and cognitive 
impairment some years later. There are potential biases in these data: they are 
retrospective, based on the most recent clinic visit, and the tools for identifying apathy and 
cognitive impairment are insensitive. Furthermore, the use of medications such as 
antidyskinetics and antidepressants is found in up to 60% of HD patients and might 
influence phenotypes12,44- although probably not symptom onsets given that medications 
are usually prescribed reactively. These data contrast with the physician estimates of initial 
HD symptom from REGISTRY where motor is by far the most common presenting symptom 
over the age of 20 (Fig. 1A). This apparent discrepancy arises as the HD-CCQ records the 
lifetime prevalence of symptoms in individuals with HD irrespective of whether they are 
considered directly due to HD. Psychiatric symptoms in ‘pre-manifest’ individuals carrying 
the HD mutation have often been attributed to co-incident diagnoses rather than HD itself. 
This is particularly true of depression which is common in non-HD populations of young 
adults45–47. However, rates of depression given by the HD-CCQ are at the higher end of the 
previously reported 33-70% prevalence rate in HD, depending on whether studies were 
reporting depressive symptoms (higher estimates), or a formal diagnosis of depressive 
disorder (lower estimates)3. 
Our finding that psychosis in HD was negatively associated with educational level (Table 3) 
agrees with previous work showing that higher levels of education are associated with 
decreased schizophrenia risk48. Recent genetic evidence has shown that polygenic risk 
scores for psychiatric disorders, particularly depression and schizophrenia, are associated 
with increased risk of corresponding psychiatric symptoms in HD49.  This suggests that the 
increased frequency of psychiatric symptoms in HD compared with the general population 
may be partly due to the presence of an expanded CAG repeat in HTT lowering the genetic 
threshold for manifestation of such symptoms49, and so the associations observed with 
these symptoms in the general population should also be observed in HD cases. In 
agreement, we found the expected relationships between female sex and depression and 
male sex and irritability in our cohort (Table 3). Overall, these data argue that psychiatric 
symptoms manifesting at any age in an individual carrying the HD mutation should be 
considered part of the disease phenotype. 
In conclusion, detailed information on the onset of different symptoms in HD enables 
quantitative analyses of symptom relationships at both the individual and population level. 
These data show that multiple symptoms occur in the majority of individuals with HD and 
that, unsurprisingly, their presence is related to CAG length. The presence of psychiatric and 
behavioural symptoms in HD patients is associated with significantly reduced functional 
capacity, emphasising the importance of managing these symptoms that have deleterious 
effects on quality of life50,51. It is notable that recent models of HD staging and progression 
do not directly include these psychiatric and behavioural symptoms that the patients and 
their carers find most difficult and distressing52–54. Work is underway to include detailed 
ratings of psychiatric symptoms in ongoing observational studies, as well as in clinical trials, 
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in order to capture the full breadth of the HD phenotype and improve the accuracy of 
clinical outcome measures. 
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Mainline figures & tables 
Figure 1. The initial symptom of HD varies by age and CAG length. All included individuals 
had a pathogenic CAG length (36-93) and confirmed HD onset age determined by a rating 
clinician. (A) Frequency of different onset types in four age groups, chosen to show juvenile 
HD and then 20 year bins for clarity. Total N=6289; <20 years, N=188; 20-40 years, N=2216; 
40-60 years, N=3276; >60 years, N=609. (B) Frequency of different onset types in six CAG
length groups, chosen for clarity across the pathogenic range. Total N=6289; 36-39 CAG,
N=156; 40-44 CAG, N=3813; 45-49 CAG, N=1735; 50-54 CAG, N=387; 55-59 CAG, N=97; >60
CAG, N=101.
A 
B 
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Figure 2. Mean ages at onset for motor and psychiatric symptoms at different CAG repeat 
lengths. Shown are the mean symptom ages as recorded by the HD Clinical Characteristics 
Questionnaire for apathy (N = 2739), cognitive impairment (N = 3069), depression (N = 
3399), irritability (N = 3117) and motor symptoms (N = 4889). Numerical data, as well as 
data for perseverative/obsessive behaviour (POB), violent or aggressive behaviour (VAB) 
and psychosis (PSY) symptoms, are shown in Table S4. 
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Males Females 
Yes No Frequency Yes No Frequency P value (2) 
Motor 2691 28 98.97% 2859 25 99.13% 5.29 x 10-1 
Cognitive 1584 1132 58.32% 1688 1187 58.71% 7.66 x 10-1 
Apathy 1456 1259 53.63% 1495 1374 52.11% 2.56 x 10-1 
Depression 1582 1135 58.23% 2025 853 70.36% 2.57 x 10-21 
POB 1005 1711 37.00% 1038 1834 36.14% 5.04 x 10-1 
Irritability 1706 1006 62.91% 1634 1240 56.85% 4.03 x 10-6 
VAB 947 1769 34.87% 777 2100 27.01% 1.99 x 10-10 
Psychosis 319 2396 11.75% 325 2549 11.31% 6.06 x 10-1 
Table 1. Lifetime prevalence of motor and psychiatric symptoms in males and females with 
HD. Data from HD Clinical Characteristics Questionnaire at last recorded clinic visit in 
Registry. Chi-square tests the difference between prevalence in males and females. 
Significant P values in bold (P < 6.25 x 10-3, multiple testing correction). POB: 
perseverative/obsessive behaviour; VAB: violent or aggressive behaviour.
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Male Female 
P 
Both 
R2 N R2 N R2 N 
Motor 0.678 2684 0.649 2844 5.42 x 10-2 0.663 5528 
Cognitive 0.610 1570 0.629 1681 3.80 x 10-1 0.619 3251 
Apathy 0.595 1423 0.562 1462 1.83 x 10-1 0.578 2885 
Depression 0.412 1551 0.351 1994 3.50 x 10-2 0.375 3545 
POB 0.539 973 0.440 1016 3.67 x 10-3 0.489 1989 
Irritability 0.463 1670 0.547 1601 1.25 x 10-3 0.503 3271 
VAB 0.479 927 0.478 761 9.79 x 10-1 0.477 1688 
Psychosis 0.401 312 0.424 318 7.29 x 10-1 0.411 630 
Table 2. Variance in age at onset (R2) explained by pathogenic CAG repeat length for eight 
symptoms in males and females with HD. Ages at onset were logarithmically transformed 
and plotted against CAG length. P values test difference between male and female R2. 
Significant P values (P < 6.25 x 10-3) are in bold and nominally significant P values (P < 0.05) 
italicised. Individuals had to have a clinical onset of HD, a known sex and a pathogenic CAG 
length (36-93) to be included. POB: perseverative/obsessive behaviour; VAB: violent or 
aggressive behaviour. 
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Motor (N=1465) Cognitive (N=1465) Apathy (N=1465) 
Depression 
(N=1467) 
β P β P β P β P 
Sex -4.898 2.20 x 10-1 0.176 1.36 x 10-1 0.027 8.07 x 10-1 0.543 2.49 x 10-6 
CAG -6.252 1.23 x 10-1 -0.021 8.62 x 10-1 0.101 3.60 x 10-1 -0.206 7.64 x 10-2
Alcohol -1.348 7.01 x 10-1 0.301 1.79 x 10-2 0.036 7.44 x 10-1 -0.193 9.29 x 10-2
Tobacco 11.498 1.60 x 10-1 0.099 4.04 x 10-1 0.201 7.09 x 10-2 0.316 9.91 x 10-3
Education -3.975 3.16 x 10-1 0.109 3.62 x 10-1 -0.176 1.11 x 10-1 -0.087 4.58 x 10-1
TFC 5.799 4.23 x 10-1 -2.095 9.09 x 10-28 -1.115 9.88 x 10-11 -0.988 7.13 x 10-8
TMS 43.080 1.48 x 10-4 -0.302 1.03 x 10-1 -0.273 1.10 x 10-1 -0.759 3.39 x 10-5
POB (N=1464) Irritability (N=1467) VAB (N=1467) Psychosis (N=1464) 
β P β P β P β P 
Sex 0.068 5.97 x 10-1 -0.324 3.69 x 10-3 -0.308 2.22 x 10-2 -0.391 2.79 x 10-1
CAG -0.156 2.36 x 10-1 0.009 9.35 x 10-1 0.183 1.69 x 10-1 -0.395 2.95 x 10-1
Alcohol 0.143 2.53 x 10-1 0.151 2.15 x 10-1 0.068 6.02 x 10-1 0.431 1.51 x 10-1 
Tobacco 0.062 6.31 x 10-1 0.347 3.10 x 10-3 0.267 4.01 x 10-2 0.003 9.93 x 10-1 
Education -0.026 8.40 x 10-1 -0.055 6.26 x 10-1 -0.189 1.67 x 10-1 -1.334 4.71 x 10-4
TFC -1.109 3.52 x 10-8 -0.754 1.65 x 10-5 -1.183 1.95 x 10-8 -2.364 3.05 x 10-5
TMS -0.252 2.01 x 10-1 -0.446 1.06 x 10-2 -0.299 1.46 x 10-1 -0.414 4.38 x 10-1
Table 3. Multiple logistic regression of the lifetime presence or absence of eight HD symptoms on clinical covariates. Binary HD-CCQ data were 
used (0 = no symptom; 1 = reported symptom). Significant associations after Bonferroni correction for 8 symptoms are shown in bold (P < 6.25 
x 10-3) and nominally significant associations in italics (P < 0.05). In addition to having a confirmed onset and pathogenic CAG length, 
individuals must have had onset ≥ 20 years, TFC > 0 and no co-morbid diagnosis of schizophrenia, schizotypy or schizoaffective disorder. β: 
standardised coefficient; POB: perseverative/obsessive behaviour; TFC: total functional capacity; TMS: total motor score; VAB: violent or 
aggressive behaviour. 
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